Pfizer is looking to enter the growing weight loss drug market, which it believes could be worth $90 billion, and wants to capture $10 billion of that segment. The company's experimental obesity pill danuglipron will release phase 2 trial data by the end of 2023, showing its effects in obese patients without diabetes. Eli Lilly's pill resulted in average weight losses of up to 14.7% in clinical trials. Novo Nordisk's oral semaglutide drug Rybelsus also showed average weight losses of 15.1% in trials. Analysts say for danuglipron to be competitive, it needs to show mid-teens percentage weight loss in its upcoming trials.